Advertisement

Ads Placeholder
Loading...

BRAIN Biotech AG

BNN.DEXETRA
Healthcare
Biotechnology
2.48
0.06(2.48%)
German Market is Open • 11:45

BRAIN Biotech AG (BNN.DE) Stock Competitors & Peer Comparison

See (BNN.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BNN.DE€2.48+2.48%54.2M-5.06-€0.49N/A
NOV.DE€31.93+2.01%141.8B10.36€3.08+4.05%
VX1.DE€382.95-1.63%97.3B28.64€13.37N/A
DUL.DE€276.30-2.78%36.6B136.61€2.02N/A
22UA.F€77.40+0.45%19.5B-16.47-€4.70N/A
0QF.F€41.78-4.43%16.5B-6.66-€6.27N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
BBZA.DE€48.35+0.31%2.7B-5.62-€8.60+5.11%
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BNN.DE vs NOV.DE Comparison April 2026

BNN.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNN.DE stands at 54.2M. In comparison, NOV.DE has a market cap of 141.8B. Regarding current trading prices, BNN.DE is priced at €2.48, while NOV.DE trades at €31.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNN.DE currently has a P/E ratio of -5.06, whereas NOV.DE's P/E ratio is 10.36. In terms of profitability, BNN.DE's ROE is -3.38%, compared to NOV.DE's ROE of +0.61%. Regarding short-term risk, BNN.DE is more volatile compared to NOV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for BNN.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions